Company intelligence / Profile preview
Marathon Pharmaceuticals
Northbrook, Illinois, United Statesmarathonpharma.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
Marathon Pharmaceuticals developed Emflaza (deflazacort), a glucocorticoid for treating Duchenne muscular dystrophy. The drug received FDA approval in February 2017, but the company faced significant backlash over its pricing strategy ($89,000 per year compared to $1,000 in other countries). Shortly after approval, Marathon sold the rights to Emflaza to PTC Therapeutics for $140 million plus potential milestone payments and royalties[2][7].
- Therapeutic areas
- GastroenterologyHematologyRare DiseasesNeurology
- Modalities
- Small moleculesglucocorticoids
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
National Organization of Rare Disorders (NORD)
Beyond the preview
Go deeper on Marathon Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Marathon Pharmaceuticals.